Expired
Lead Plaintiff Deadline
Aug 17, 2021
Choose your preferred way to stay informed of new case launches and settlement deadlines
(i) the information submitted to the U.S. Food and Drug Administration (“FDA”) was insufficient to support an Emergency Use Authorization (“EUA”), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Ocugen’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
In order to be eligible to join the OCGN class action lawsuit, you must have incurred a loss on shares of Ocugen purchased during the class period listed above.
If you suffered a loss in Ocugen during the relevant time frame or pursuant to the relevant offering(s), you have until August 17, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
